

Paul G Richardson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5949616/publications.pdf>

Version: 2024-02-01

883
papers

89,559
citations

255

142
h-index

407

277
g-index

889
all docs

889
docs citations

889
times ranked

45435
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
2	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. <i>New England Journal of Medicine</i> , 2003, 348, 2609-2617.	13.9	2,460
3	BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. <i>Cell</i> , 2011, 146, 904-917.	13.5	2,432
4	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2005, 352, 2487-2498.	13.9	2,356
5	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
6	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 2008, 359, 906-917.	13.9	1,787
7	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
8	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	13.9	1,210
9	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	13.9	1,139
10	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1770-1781.	13.9	1,024
11	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1207-1219.	13.9	948
12	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 376, 1311-1320.	13.9	924
13	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> , 2001, 98, 210-216.	0.6	869
14	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	13.9	861
15	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	0.6	849
16	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	7.7	847
17	Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. <i>Blood</i> , 2000, 96, 2943-2950.	0.6	844
18	NF- κ B as a Therapeutic Target in Multiple Myeloma. <i>Journal of Biological Chemistry</i> , 2002, 277, 16639-16647.	1.6	824

#	ARTICLE	IF	CITATIONS
19	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. <i>Nature Reviews Cancer</i> , 2007, 7, 585-598.	12.8	817
20	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2010, 116, 679-686.	0.6	790
21	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood</i> , 2002, 100, 3063-3067.	0.6	759
22	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014, 5, 2997.	5.8	741
23	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1551-1560.	6.3	724
24	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 1195-1206.	5.1	695
25	Molecular sequelae of proteasome inhibition in human multiple myeloma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 14374-14379.	3.3	691
26	Multiple myeloma. <i>Lancet, The</i> , 2009, 374, 324-339.	6.3	685
27	The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. <i>Blood</i> , 2003, 101, 2377-2380.	0.6	678
28	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. <i>Cancer Cell</i> , 2005, 8, 407-419.	7.7	673
29	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
30	Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. <i>Blood</i> , 2002, 99, 4525-4530.	0.6	640
31	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, 3113-3120.	0.8	587
32	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
33	Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8567-8572.	3.3	571
34	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2020, 21, 207-221.	5.1	544
35	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	0.8	535
36	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. <i>Blood</i> , 2003, 101, 1530-1534.	0.6	533

#	ARTICLE	IF	CITATIONS
37	Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 630-639.	0.8	526
38	Hepatic Venous Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 157-168.	2.0	509
39	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. <i>Blood</i> , 2006, 108, 3458-3464.	0.6	494
40	A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance. <i>Cancer Cell</i> , 2012, 22, 345-358.	7.7	491
41	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , 2007, 110, 3557-3560.	0.6	485
42	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
43	Activation of NF- κ B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. <i>Oncogene</i> , 2002, 21, 5673-5683.	2.6	456
44	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. <i>Blood</i> , 2008, 112, 1329-1337.	0.6	439
45	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012, 120, 947-959.	0.6	438
46	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020, 136, 936-945.	0.6	436
47	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , 2019, 394, 2096-2107.	6.3	435
48	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018, 379, 1811-1822.	13.9	413
49	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2259-2266.	0.8	403
50	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. <i>Blood</i> , 2001, 98, 428-435.	0.6	399
51	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. <i>Blood</i> , 2006, 107, 4053-4062.	0.6	398
52	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i> , 2012, 119, 4375-4382.	0.6	396
53	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , 2017, 18, e206-e217.	5.1	394
54	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. <i>Blood</i> , 2007, 109, 3177-3188.	0.6	379

#	ARTICLE	IF	CITATIONS
55	The role of tumor necrosis factor $\hat{\pm}$ in the pathophysiology of human multiple myeloma: therapeutic applications. <i>Oncogene</i> , 2001, 20, 4519-4527.	2.6	376
56	Biologic sequelae of nuclear factor $\hat{\pm}$ blockade in multiple myeloma: therapeutic applications. <i>Blood</i> , 2002, 99, 4079-4086.	0.6	369
57	Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. <i>Cancer Research</i> , 2002, 62, 4996-5000.	0.4	362
58	Novel anti $\hat{\pm}$ -cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> , 2014, 123, 3128-3138.	0.6	361
59	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	0.8	358
60	TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. <i>Blood</i> , 2001, 98, 795-804.	0.6	357
61	Blockade of XBP1 splicing by inhibition of IRE1 $\hat{\pm}$ is a promising therapeutic option in multiple myeloma. <i>Blood</i> , 2012, 119, 5772-5781.	0.6	353
62	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 128, 37-44.	0.6	347
63	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. <i>Blood</i> , 2013, 121, 2975-2987.	0.6	335
64	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	0.8	330
65	Bortezomib induces canonical nuclear factor $\hat{\pm}$ activation in multiple myeloma cells. <i>Blood</i> , 2009, 114, 1046-1052.	0.6	329
66	CD38 antibodies in multiple myeloma: back to the future. <i>Blood</i> , 2018, 131, 13-29.	0.6	329
67	Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. <i>Blood</i> , 2002, 100, 4337-4343.	0.6	328
68	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014, 123, 1826-1832.	0.6	327
69	Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. <i>Annual Review of Medicine</i> , 2006, 57, 33-47.	5.0	317
70	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. <i>Blood</i> , 2005, 106, 3777-3784.	0.6	306
71	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. <i>British Journal of Haematology</i> , 2005, 128, 192-203.	1.2	305
72	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018, 132, 2456-2464.	0.6	301

#	ARTICLE	IF	CITATIONS
73	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2003, 102, 1578-1582.	0.6	299
74	Molecular sequelae of histone deacetylase inhibition in human malignant B cells. <i>Blood</i> , 2003, 101, 4055-4062.	0.6	296
75	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	0.8	294
76	<i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 5311-5321.	3.2	290
77	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose modification guideline. <i>British Journal of Haematology</i> , 2009, 144, 895-903.	1.2	289
78	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
79	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. <i>Nature Medicine</i> , 2010, 16, 483-489.	15.2	281
80	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. <i>Blood</i> , 2013, 122, 2331-2337.	0.6	281
81	Antimyeloma activity of heat shock protein-90 inhibition. <i>Blood</i> , 2005, 107, 1092-1100.	0.6	278
82	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4607-4618.	3.2	271
83	Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers. <i>Cancer Control</i> , 2003, 10, 361-369.	0.7	269
84	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. <i>Blood</i> , 2004, 103, 1787-1790.	0.6	266
85	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	5.1	256
86	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016, 127, 1656-1665.	0.6	255
87	A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. <i>Blood</i> , 2014, 123, 706-716.	0.6	254
88	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	5.1	254
89	Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 448-455.	0.8	250
90	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. <i>Nature Medicine</i> , 2014, 20, 599-606.	15.2	250

#	ARTICLE	IF	CITATIONS
91	Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAiEM Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2911-2918.	0.8	247
92	Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2034-2042.	1.9	246
93	A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. <i>Blood</i> , 2010, 115, 5202-5213.	0.6	245
94	Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4784-4790.	0.8	244
95	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. <i>Blood</i> , 2016, 127, 3225-3236.	0.6	244
96	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. <i>Blood</i> , 2007, 109, 2604-2606.	0.6	242
97	Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target. <i>Cancer Cell</i> , 2009, 16, 309-323.	7.7	242
98	Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3518-3525.	0.8	241
99	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1503-1512.	5.1	233
100	The proteasome and proteasome inhibitors in multiple myeloma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 561-584.	2.7	229
101	Defibrotide for the Treatment of Severe Hepatic Venoo-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1005-1017.	2.0	227
102	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. <i>Blood</i> , 2003, 102, 2615-2622.	0.6	220
103	Proton Pump Inhibitors. <i>Drugs</i> , 1998, 56, 307-335.	4.9	219
104	Bortezomib in recurrent and/or refractory multiple myeloma. <i>Cancer</i> , 2005, 103, 1195-1200.	2.0	218
105	High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 183-196.	2.0	216
106	Role of B-Cell-Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. <i>Cancer Research</i> , 2006, 66, 6675-6682.	0.4	212
107	Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4767-4773.	3.2	212
108	Resolving the daratumumab interference with blood compatibility testing. <i>Transfusion</i> , 2015, 55, 1545-1554.	0.8	204

#	ARTICLE	IF	CITATIONS
109	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 3307-3315.	3.2	203
110	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. <i>Blood</i> , 2010, 116, 3227-3237.	0.6	202
111	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>in vitro</i> and <i>in vivo</i> . <i>Clinical Cancer Research</i> , 2009, 15, 4028-4037.	3.2	200
112	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. <i>Blood</i> , 2011, 117, 393-402.	0.6	199
113	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger <i>in vivo</i> synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2008, 111, 1654-1664.	0.6	193
114	Latest advances and current challenges in the treatment of multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 135-143.	12.5	193
115	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology</i> , 2018, 19, 1641-1653.	5.1	193
116	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. <i>Blood</i> , 2014, 124, 1038-1046.	0.6	192
117	The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. <i>European Journal of Cancer</i> , 2006, 42, 1564-1573.	1.3	188
118	A novel orally active proteasome inhibitor ONX 0912 triggers <i>in vitro</i> and <i>in vivo</i> cytotoxicity in multiple myeloma. <i>Blood</i> , 2010, 116, 4906-4915.	0.6	188
119	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , 2020, 396, 1563-1573.	6.3	188
120	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 502-507.	0.6	185
121	Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1960-1965.	0.8	184
122	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 131, 71-73.	1.2	180
123	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016, 127, 681-695.	0.6	179
124	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.	0.6	178
125	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , 2004, 104, 4188-4193.	0.6	177
126	PI3K/p110 β is a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2010, 116, 1460-1468.	0.6	177

#	ARTICLE	IF	CITATIONS
127	Current treatment landscape for relapsed and/or refractory multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 42-54.	12.5	175
128	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , 2014, 123, 1461-1469.	0.6	174
129	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 132-147.	13.9	173
130	Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays. <i>Oncogene</i> , 2002, 21, 1346-1358.	2.6	170
131	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	2.8	170
132	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. <i>Blood</i> , 2005, 106, 1794-1800.	0.6	167
133	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001, 28, 607-612.	0.8	164
134	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1569-1578.	5.1	164
135	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. <i>Oncogene</i> , 2003, 22, 8386-8393.	2.6	163
136	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40â€œInduced Cytotoxicity in Human Multiple Myeloma: Clinical Implications. <i>Cancer Research</i> , 2005, 65, 11712-11720.	0.4	163
137	Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5713-5719.	0.8	155
138	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 1317-1330.	5.1	155
139	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6086-6093.	0.8	154
140	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008, 112, 4425-4431.	0.6	153
141	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Antiâ€œInsulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3196-3203.	0.8	152
142	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. <i>Blood</i> , 2013, 121, 1961-1967.	0.6	152
143	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstr�m Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1422-1428.	0.8	150
144	Proteasome inhibitor therapy in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 686-692.	1.9	148

#	ARTICLE	IF	CITATIONS
145	Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma. <i>Cancer Research</i> , 2005, 65, 5898-5906.	0.4	146
146	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
147	New Drugs for Myeloma. <i>Oncologist</i> , 2007, 12, 664-689.	1.9	145
148	Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2009, 114, 772-778.	0.6	145
149	A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 2764-2767.	0.6	143
150	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. <i>Blood</i> , 2011, 117, 4409-4419.	0.6	141
151	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b/2 dose-escalation study. <i>Lancet Haematology</i> , 2015, 2, e516-e527.	2.2	140
152	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , 2021, 22, e105-e118.	5.1	136
153	Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2555.	3.8	134
154	Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma. <i>Cancer</i> , 2006, 106, 1316-1319.	2.0	133
155	Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw. <i>Clinical Cancer Research</i> , 2008, 14, 2387-2395.	3.2	133
156	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	2.2	132
157	Cytokines modulate telomerase activity in a human multiple myeloma cell line. <i>Cancer Research</i> , 2002, 62, 3876-82.	0.4	131
158	MLN120B, a Novel $\text{I}\beta\text{B}$ Kinase I^2 Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 5887-5894.	3.2	130
159	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001, 28, 607-612.	0.8	130
160	Thalidomide: Emerging Role in Cancer Medicine. <i>Annual Review of Medicine</i> , 2002, 53, 629-657.	5.0	128
161	Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. <i>Current Opinion in Hematology</i> , 2003, 10, 451-462.	1.2	128
162	The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , 2002, 62, 5019-26.	0.4	128

#	ARTICLE	IF	CITATIONS
163	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. <i>Oncogene</i> , 2004, 23, 8766-8776.	2.6	127
164	Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. <i>Cancer Research</i> , 2004, 64, 2846-2852.	0.4	126
165	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. <i>European Journal of Haematology</i> , 2011, 86, 23-31.	1.1	126
166	Kidney Disease and Multiple Myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2007-2017.	2.2	125
167	Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3696-3703.	0.8	123
168	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. <i>Blood</i> , 2004, 103, 3158-3166.	0.6	122
169	How I treat multiple myeloma in younger patients. <i>Blood</i> , 2009, 114, 5436-5443.	0.6	122
170	Multiple Myeloma. <i>Annual Review of Medicine</i> , 2011, 62, 249-264.	5.0	121
171	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	0.6	121
172	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e506-e515.	2.2	121
173	Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity. <i>Mayo Clinic Proceedings</i> , 2004, 79, 875-882.	1.4	120
174	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT follow-up and post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	1.2	120
175	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Haematology</i> , 2010, 149, 537-549.	1.2	119
176	Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. <i>Haematologica</i> , 2006, 91, 929-34.	1.7	119
177	Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. <i>British Journal of Haematology</i> , 2011, 152, 367-379.	1.2	118
178	Treatment Options for Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1264-1277.	3.2	118
179	Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4243-4249.	0.8	118
180	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT trial. <i>Cancer</i> , 2018, 124, 4032-4043.	2.0	118

#	ARTICLE	IF	CITATIONS
181	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-eligible multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 222-230.	1.2	118
182	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007, 137, 429-435.	1.2	115
183	How I treat plasma cell leukemia. <i>Blood</i> , 2012, 120, 2376-2389.	0.6	115
184	Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. <i>Blood</i> , 2003, 101, 703-705.	0.6	114
185	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13162-13167.	3.3	112
186	Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. <i>Clinical Cancer Research</i> , 2004, 10, 7540-7546.	3.2	111
187	2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. <i>Blood</i> , 2002, 100, 2187-2194.	0.6	110
188	The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1007-1034.	0.9	110
189	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	0.8	110
190	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. <i>Blood</i> , 2007, 110, 1656-1663.	0.6	106
191	Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2010, 115, 834-845.	0.6	104
192	Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 851-60.	1.9	104
193	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , 2007, 138, 783-791.	1.2	102
194	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. <i>British Journal of Haematology</i> , 2011, 153, 729-740.	1.2	102
195	A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Preliminary Results. <i>Blood</i> , 2005, 106, 1565-1565.	0.6	102
196	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010, 116, 3743-3750.	0.6	101
197	The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 539-44.	1.9	101
198	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. <i>Cancer</i> , 2005, 104, 2141-2148.	2.0	99

#	ARTICLE	IF	CITATIONS
199	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergrupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , 2015, 126, 391-391.	0.6	99
200	Aplidin, a Marine Organismâ€‘Derived Compound with Potent Antimyeloma Activity <i>In vitro</i> and <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 5216-5225.	0.4	98
201	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. <i>Blood</i> , 2014, 123, 632-639.	0.6	98
202	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2016, 128, 1821-1828.	0.6	98
203	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	5.8	98
204	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	0.8	98
205	FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance. <i>Cancer Research</i> , 2005, 65, 7478-7484.	0.4	97
206	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. <i>Cancer Discovery</i> , 2015, 5, 972-987.	7.7	97
207	Final results from a defibrotide treatmentâ€‘IND study for patients with hepatic venoâ€‘occlusive disease/sinusoidal obstruction syndrome. <i>British Journal of Haematology</i> , 2018, 181, 816-827.	1.2	95
208	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 46-53.	1.2	94
209	Proteasome Inhibition in the Treatment of Cancer. <i>Cell Cycle</i> , 2005, 4, 289-295.	1.3	92
210	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 222-229.	1.2	91
211	Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 623-633.	1.5	90
212	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	0.6	90
213	New Proteasome Inhibitors in Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 258-266.	1.2	89
214	TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 400-405.	2.0	89
215	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016, 127, 1138-1150.	0.6	89
216	Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2011, 12, 263-272.	5.1	88

#	ARTICLE	IF	CITATIONS
217	GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Blood</i> , 2004, 103, 3474-3479.	0.6	87
218	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016, 7, 10258.	5.8	87
219	Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib. <i>Cancer Research</i> , 2004, 64, 7500-7506.	0.4	86
220	<i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2013, 19, 3019-3031.	3.2	86
221	Promising therapies in multiple myeloma. <i>Blood</i> , 2015, 126, 300-310.	0.6	86
222	Prediction of Venous Occlusive Disease Using Biomarkers of Endothelial Injury. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1180-1185.	2.0	85
223	Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 537-540.	1.2	84
224	THE PATHOLOGY, DIAGNOSIS, AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE: CURRENT STATUS AND NOVEL APPROACHES. <i>British Journal of Haematology</i> , 1999, 107, 485-493.	1.2	83
225	Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 950-968.	1.2	83
226	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. <i>Blood</i> , 2011, 118, 535-543.	0.6	82
227	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>Blood</i> , 2019, 134, 123-133.	0.6	82
228	Clinical update: proteasome inhibitors in hematologic malignancies. <i>Cancer Treatment Reviews</i> , 2003, 29, 33-39.	3.4	79
229	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. <i>Blood</i> , 2004, 104, 2458-2466.	0.6	79
230	Bortezomib in the front-line treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1053-1072.	1.1	79
231	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 146, 164-170.	1.2	79
232	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e45-e54.	2.2	79
233	Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1916-1923.	0.8	78
234	Defibrotide for the Treatment of Hepatic Venous Occlusive Disease: Final Results From the International Compassionate-Use Program. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1874-1882.	2.0	78

#	ARTICLE	IF	CITATIONS
235	Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies. <i>JAMA Oncology</i> , 2017, 3, 980.	3.4	77
236	Multiple Myeloma. Hematology American Society of Hematology Education Program, 2004, 2004, 237-256.	0.9	76
237	Dual Inhibition of Canonical and Noncanonical NF- κ B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2012, 18, 4669-4681.	3.2	75
238	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. <i>British Journal of Haematology</i> , 2004, 125, 343-352.	1.2	74
239	Intracellular NAD ⁺ depletion enhances bortezomib-induced anti-myeloma activity. <i>Blood</i> , 2013, 122, 1243-1255.	0.6	74
240	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 8-17.e16.	0.2	74
241	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , 2020, 7, e447-e455.	2.2	74
242	Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. <i>British Journal of Haematology</i> , 2005, 132, 051220022257014.	1.2	73
243	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. <i>Haematologica</i> , 2011, 96, 1170-1179.	1.7	72
244	Drug safety evaluation of defibrotide. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 123-136.	1.0	72
245	Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 112-118.	1.2	72
246	Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. <i>Blood</i> , 2012, 120, 3958-3967.	0.6	71
247	Guidelines for determination of the number of prior lines of therapy in multiple myeloma. <i>Blood</i> , 2015, 126, 921-922.	0.6	71
248	Biologic sequelae of κ B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. <i>Blood</i> , 2009, 113, 5228-5236.	0.6	70
249	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. <i>Blood</i> , 2020, 136, 39-39.	0.6	70
250	Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6345-6350.	0.8	69
251	Sequence analysis of β -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. <i>Blood</i> , 2012, 120, 4513-4516.	0.6	69
252	Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3212-3214.	0.8	68

#	ARTICLE	IF	CITATIONS
253	Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma. <i>Clinical Cancer Research</i> , 2007, 13, 6162-6167.	3.2	68
254	Monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2011, 154, 745-754.	1.2	68
255	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
256	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. <i>British Journal of Haematology</i> , 2015, 169, 843-850.	1.2	66
257	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , 2016, 127, 2693-2700.	0.6	66
258	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 344-353.	3.2	66
259	Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. <i>Clinical Cancer Research</i> , 2009, 15, 7153-7160.	3.2	65
260	Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. <i>British Journal of Haematology</i> , 2010, 150, 428-437.	1.2	65
261	Current strategies for treatment of relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 97-111.	1.0	65
262	Melflufen - a peptidase-potentiated alkylating agent in clinical trials. <i>Oncotarget</i> , 2017, 8, 66641-66655.	0.8	65
263	Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. <i>Future Oncology</i> , 2018, 14, 1035-1047.	1.1	65
264	Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1&2 study. <i>Lancet Haematology</i> , 2020, 7, e395-e407.	2.2	65
265	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. <i>Blood Cancer Discovery</i> , 2021, 2, 468-483.	2.6	64
266	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 797-816.	0.7	63
267	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. <i>Cancer Research</i> , 2014, 74, 4458-4469.	0.4	63
268	Trial designs for chemotherapy-induced peripheral neuropathy prevention. <i>Neurology</i> , 2018, 91, 403-413.	1.5	63
269	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, e183267.	3.4	63
270	Management of the Relapsed/Refractory Myeloma Patient: Strategies Incorporating Lenalidomide. <i>Seminars in Hematology</i> , 2005, 42, S9-S15.	1.8	62

#	ARTICLE	IF	CITATIONS
271	Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. <i>British Journal of Haematology</i> , 2010, 150, 438-445.	1.2	62
272	Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2010, 16, 3260-3269.	3.2	62
273	Genetic variation associated with bortezomib-induced peripheral neuropathy. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 121-129.	0.7	62
274	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1357-1368.	1.1	62
275	A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI0052107): final study results. <i>British Journal of Haematology</i> , 2018, 180, 41-51.	1.2	62
276	Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2001, 106, 57-68.	0.7	61
277	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	1.3	61
278	Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. <i>Blood</i> , 2012, 120, 73-73.	0.6	60
279	Proteasome inhibition in hematologic malignancies. <i>Annals of Medicine</i> , 2004, 36, 304-314.	1.5	59
280	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. <i>Blood</i> , 2005, 105, 4470-4476.	0.6	59
281	The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 149-162.	2.3	59
282	Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment. <i>Clinical Cancer Research</i> , 2008, 14, 865-874.	3.2	59
283	APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. <i>Leukemia</i> , 2019, 33, 426-438.	3.3	59
284	Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. <i>Blood</i> , 2008, 112, 4343-4352.	0.6	58
285	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. <i>American Journal of Hematology</i> , 2015, 90, 314-319.	2.0	58
286	Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. <i>Investigational New Drugs</i> , 2020, 38, 1448-1453.	1.2	58
287	Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). <i>Bone Marrow Transplantation</i> , 2019, 54, 1951-1962.	1.3	57
288	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	2.8	57

#	ARTICLE	IF	CITATIONS
289	Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. <i>Haematologica</i> , 2011, 96, 1662-1669.	1.7	56
290	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 137.	6.9	56
291	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , 2020, 7, e61-e72.	2.2	56
292	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	0.6	56
293	Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. <i>British Journal of Haematology</i> , 2008, 143, 511-519.	1.2	55
294	Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. <i>British Journal of Haematology</i> , 2012, 158, 472-480.	1.2	55
295	Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib. <i>Seminars in Hematology</i> , 2009, 46, 166-175.	1.8	54
296	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014, 124, 3110-3117.	0.6	54
297	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	0.6	54
298	The use of defibrotide in blood and marrow transplantation. <i>Blood Advances</i> , 2018, 2, 1495-1509.	2.5	54
299	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. <i>Cell Reports</i> , 2021, 34, 108532.	2.9	54
300	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , 2022, 23, 416-427.	5.1	54
301	The Treatment of Relapsed and Refractory Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 317-323.	0.9	53
302	Defibrotide for Treatment of Severe Venous Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1306-1312.	2.0	53
303	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	0.8	53
304	Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome. <i>Journal of Clinical Oncology</i> , 1999, 17, 1175-1175.	0.8	50
305	Lenalidomide in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1165-1173.	1.1	50
306	Kidney disease associated with plasma cell dyscrasias. <i>Blood</i> , 2010, 116, 1397-1404.	0.6	50

#	ARTICLE	IF	CITATIONS
307	Conservative management of bisphosphonate-related osteonecrosis of the jaws: Staging and treatment outcomes. <i>Oral Oncology</i> , 2013, 49, 977-983.	0.8	50
308	Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 942-951.	1.9	49
309	A novel alkylating agent Melflufen induces irreversible <scp>DNA</scp> damage and cytotoxicity in multiple myeloma cells. <i>British Journal of Haematology</i> , 2016, 174, 397-409.	1.2	49
310	Marizomib for central nervous systemâ€multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 221-225.	1.2	49
311	COVIDâ€19â€induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021, 193, 43-51.	1.2	49
312	Bortezomib: a novel therapy approved for multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 596-600.	0.3	49
313	Emerging therapies for multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 99-127.	1.0	48
314	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. <i>Leukemia Research</i> , 2013, 37, 829-837.	0.4	48
315	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 737-748.	1.1	48
316	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560.	1.2	48
317	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i> . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017, 102, 1767-1775.	1.7	48
318	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3616-3628.	0.6	48
319	Defibrotide, a Polydisperse Mixture of Single-stranded Phosphodiester Oligonucleotides with Lifesaving Activity in Severe Hepatic Venocclusive Disease: Clinical Outcomes and Potential Mechanisms of Action. <i>Oligonucleotides</i> , 2006, 16, 105-114.	2.7	47
320	Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias. <i>Clinical Cancer Research</i> , 2009, 15, 1210-1221.	3.2	47
321	Defibrotide for Patients with Hepatic Venocclusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 997-1004.	2.0	47
322	Novel biological therapies for the treatment of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 619-634.	0.7	46
323	Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 233-235.	1.4	46
324	Selinexor for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 399-408.	0.9	46

#	ARTICLE	IF	CITATIONS
325	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	5.1	46
326	Novel biologically based therapies for Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 309-312.	0.8	45
327	Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2003, 121, 592-596.	1.2	45
328	Daratumumab granted breakthrough drug status. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 445-452.	1.9	45
329	A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. <i>Oncotarget</i> , 2016, 7, 77326-77341.	0.8	45
330	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	1.2	45
331	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	2.0	45
332	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	3.3	45
333	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 3107-3118.	0.8	45
334	Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2012, 5, 291-302.	1.0	44
335	Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. <i>British Journal of Haematology</i> , 2016, 174, 711-720.	1.2	44
336	A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 635-644.	2.0	43
337	A review of the proteasome inhibitor bortezomib in multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1321-1331.	0.9	43
338	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-1 ² inhibitors. <i>Oncogene</i> , 2005, 24, 3121-3129.	2.6	43
339	Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. <i>Shock</i> , 2022, 57, 95-105.	1.0	43
340	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	3.3	43
341	Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 755-60.	0.3	43
342	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122.	1.7	42

#	ARTICLE	IF	CITATIONS
343	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , 2018, 32, 1838-1841.	3.3	42
344	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	0.9	42
345	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1244-1253.	2.0	42
346	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 804-804.	0.6	42
347	Proteasome inhibition in the treatment of cancer. <i>Cell Cycle</i> , 2005, 4, 290-6.	1.3	42
348	Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 370-376.	0.2	41
349	Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. <i>British Journal of Haematology</i> , 2015, 171, 798-812.	1.2	41
350	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib lenalidomide dexamethasone versus placebo lenalidomide dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	2.0	41
351	Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies. <i>Current Drug Targets</i> , 2006, 7, 1341-1347.	1.0	40
352	Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Review and Update on the Use of Defibrotide. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 373-388.	1.5	40
353	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. <i>Haematologica</i> , 2010, 95, 1144-1149.	1.7	40
354	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 253-265.	1.1	40
355	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. <i>Clinical Cancer Research</i> , 2015, 21, 2660-2662.	3.2	40
356	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 106.	2.8	40
357	Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.. <i>Blood</i> , 2006, 108, 405-405.	0.6	40
358	First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8500-8500.	0.8	40
359	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 734-744.	0.9	38
360	How I treat the young patient with multiple myeloma. <i>Blood</i> , 2018, 132, 1114-1124.	0.6	38

#	ARTICLE	IF	CITATIONS
361	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 39.	2.8	38
362	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2016, 128, 675-675.	0.6	38
363	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409-414.		37
364	Novel Therapies in the Treatment of Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 947-960.	2.3	37
365	The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 627-634.	0.5	37
366	Current use of monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 181, 447-459.	1.2	37
367	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 547-560.	1.3	37
368	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. <i>Blood</i> , 2019, 134, 691-691.	0.6	37
369	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. <i>Blood</i> , 2015, 126, 23-23.	0.6	37
370	Pathological crystallization of human immunoglobulins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 13359-13361.	3.3	36
371	p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2017, 129, 1308-1319.	0.6	36
372	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.	2.0	36
373	Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 336-336.	0.6	36
374	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. <i>British Journal of Haematology</i> , 2014, 166, 401-409.	1.2	35
375	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.	3.3	35
376	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3120.	1.0	35
377	Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. <i>American Journal of Hematology</i> , 2007, 82, 831-833.	2.0	34
378	A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 129-136.	0.9	34

#	ARTICLE	IF	CITATIONS
379	The evolution and impact of therapy in multiple myeloma. <i>Medical Oncology</i> , 2010, 27, 1-6.	1.2	34
380	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	1.0	34
381	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study. <i>Blood</i> , 2008, 112, 92-92.	0.6	34
382	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Future Oncology</i> , 2005, 1, 161-167.	1.1	33
383	Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-4-S-12.	2.3	33
384	A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. <i>Proteomics</i> , 2011, 11, 1391-1402.	1.3	33
385	Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3955-3961.	3.2	33
386	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, 100-106.	1.7	33
387	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , 2018, 15, 1033-1052.	1.3	33
388	Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 181, 433-446.	1.2	33
389	Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159. <i>Blood</i> , 2017, 130, 741-741.	0.6	33
390	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. <i>Current Opinion in Oncology</i> , 2006, 18, 598-608.	1.1	32
391	Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1731-1740.	1.4	32
392	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. <i>British Journal of Haematology</i> , 2018, 180, 821-830.	1.2	32
393	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	2.2	32
394	Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenström's Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 694-702.	0.6	31
395	A clinical perspective on plasma cell leukemia; current status and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 23.	2.8	31
396	Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics. <i>Blood</i> , 2008, 112, 219-219.	0.6	31

#	ARTICLE	IF	CITATIONS
397	Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma. <i>Cancer Research</i> , 2004, 64, 8746-8753.	0.4	30
398	Management of myeloma-associated renal dysfunction in the era of novel therapies. <i>Expert Review of Hematology</i> , 2012, 5, 51-68.	1.0	30
399	Pomalidomide: New immunomodulatory agent with potent antiproliferative effects. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S36-S44.	2.0	30
400	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018, 182, 495-503.	1.2	30
401	Twice-weekly ixazomib in combination with lenalidomide+dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244.	1.2	30
402	Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503). <i>Blood</i> , 2015, 126, 507-507.	0.6	30
403	Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function. <i>Blood</i> , 2012, 119, e131-e138.	0.6	29
404	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	2.0	29
405	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 478-486.	3.2	29
406	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Cancer Management and Research</i> , 2012, 4, 253.	0.9	28
407	Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. <i>Clinical Cancer Research</i> , 2016, 22, 4206-4214.	3.2	28
408	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.2	28
409	Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1133-1141.	1.9	28
410	Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. <i>Leukemia</i> , 2022, 36, 138-154.	3.3	28
411	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 16-17.	0.6	28
412	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 302-302.	0.6	28
413	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor " Microenvironment Interactions.. <i>Blood</i> , 2010, 116, 1574-1574.	0.6	28
414	Optimizing bortezomib treatment in patients with relapsed multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 4-5; discussion 8; suppl 13.	0.3	28

#	ARTICLE	IF	CITATIONS
415	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 147, 531-534.	1.2	27
416	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.	0.6	27
417	Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Venous Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1817-1825.	2.0	27
418	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 942-945.	1.3	27
419	Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 113-124.	1.3	27
420	Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. <i>Leukemia</i> , 2019, 33, 2208-2226.	3.3	27
421	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2021, 106, 1182-1187.	1.7	27
422	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	1.2	27
423	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. <i>Blood Reviews</i> , 2021, 49, 100808.	2.8	27
424	Bortezomib Continues to Demonstrate Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trial. <i>Blood</i> , 2005, 106, 2547-2547.	0.6	27
425	<i>In vitro</i> anti-myeloma activity of the Aurora kinase inhibitor VE-822. <i>British Journal of Haematology</i> , 2009, 147, 672-676.	1.2	26
426	Methyljasmonate displays <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2012, 159, 340-351.	1.2	26
427	Realgar nanoparticles versus arsenic compounds induce <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma. <i>British Journal of Haematology</i> , 2017, 179, 756-771.	1.2	26
428	Phase I Trial of CCI-779 (Temozolomide) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 3696-3696.	0.6	26
429	SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis. <i>Blood</i> , 2014, 124, 3441-3441.	0.6	26
430	Monoclonal antibodies in myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 599-609.	0.3	26
431	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2308-2315.	0.6	25
432	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 255-261.	0.9	25

#	ARTICLE	IF	CITATIONS
433	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015, 11, 1153-1168.	1.1	25
434	Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 885-898.	1.4	25
435	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017, 117, 185-191.	3.1	25
436	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27269.	0.8	25
437	A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 406-406.	0.6	25
438	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014, 124, 638-638.	0.6	25
439	Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 127-131.	1.2	24
440	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 35-48.	1.3	24
441	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017, 10, 229-237.	1.0	24
442	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 75-93.	0.7	24
443	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018, 180, 271-275.	1.2	24
444	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2018, 57, 529-538.	1.6	24
445	Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. <i>Journal of Geriatric Oncology</i> , 2019, 10, 486-489.	0.5	24
446	Prevention and Treatment of Hepatic Venocclusive Disease after High-Dose Cytoreductive Therapy. <i>Leukemia and Lymphoma</i> , 1998, 31, 267-277.	0.6	23
447	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , 2011, 4, 51-60.	1.0	23
448	Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. <i>British Journal of Haematology</i> , 2011, 152, 420-432.	1.2	23
449	Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 793-798.	2.0	23
450	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23

#	ARTICLE	IF	CITATIONS
451	The role of high-dose melphalan with autologous stem cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , 2020, 191, 692-703.	1.2	23
452	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 351-357.	0.2	23
453	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , 2021, 17, 1987-2003.	1.1	23
454	First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. <i>Blood</i> , 2016, 128, 1148-1148.	0.6	23
455	New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 734-44.	0.9	23
456	Management of Relapsed and Relapsed/Refractory Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1209-1216.	2.3	22
457	Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area. <i>Journal of Clinical Oncology</i> , 2014, 32, 2125-2132.	0.8	22
458	Isatuximab for the treatment of relapsed/refractory multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1395-1404.	1.4	22
459	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , 2015, 126, 28-28.	0.6	22
460	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. <i>Nature Cell Biology</i> , 2021, 23, 1199-1211.	4.6	22
461	A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2011, 86, 573-578.	2.0	21
462	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	1.1	21
463	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 756-763.	1.2	21
464	Combination of a Selective HSP90 α / β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2015, 10, e0143847.	1.1	20
465	Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥ 2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA trial. <i>British Journal of Haematology</i> , 2018, 181, 628-636.	1.2	20
466	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	2.0	20
467	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015, 126, 395-395.	0.6	20
468	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102) Tj ETQq0 0.0 rgBT /Overlock 10	0.0	20

#	ARTICLE	IF	CITATIONS
469	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. <i>Blood</i> , 2021, 138, 79-79.	0.6	20
470	Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. <i>British Journal of Haematology</i> , 2011, 154, 755-762.	1.2	19
471	Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. <i>British Journal of Haematology</i> , 2013, 160, 351-358.	1.2	19
472	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. <i>Targeted Oncology</i> , 2017, 12, 643-654.	1.7	19
473	New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 107-121.	0.7	19
474	Incidence of Anicteric Venous Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1342-1349.	2.0	19
475	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. <i>Leukemia Research</i> , 2021, 104, 106576.	0.4	19
476	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , 2020, 136, 45-46.	0.6	19
477	Novel Three" and Four"Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. <i>Blood</i> , 2009, 114, 127-127.	0.6	19
478	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 759-759.	0.6	19
479	Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results. <i>Blood</i> , 2015, 126, 375-375.	0.6	19
480	Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2123-2123.	0.6	19
481	New treatments for multiple myeloma. <i>Oncology</i> , 2005, 19, 1781-92; discussion 1792, 1795-7.	0.4	19
482	Novel therapies in myeloma. <i>Current Opinion in Hematology</i> , 2007, 14, 609-615.	1.2	18
483	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5688-5695.	3.2	18
484	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 475-479.	1.2	18
485	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6432-6444.	3.2	18
486	Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. <i>Blood</i> , 2007, 110, 1165-1165.	0.6	18

#	ARTICLE	IF	CITATIONS
487	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. Blood, 2009, 114, 2878-2878.	0.6	18
488	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. Blood, 2013, 122, 535-535.	0.6	18
489	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. Blood, 2014, 124, 82-82.	0.6	18
490	ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD [®]) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). Blood, 2015, 126, 3040-3040.	0.6	18
491	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evidence, 2010, 4, 215.	4.7	18
492	CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002. Blood, 2021, 138, 2731-2731.	0.6	18
493	Melflufen for relapsed and refractory multiple myeloma. Expert Opinion on Investigational Drugs, 2020, 29, 1069-1078.	1.9	17
494	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. Blood, 2018, 132, 598-598.	0.6	17
495	A Phase 1 Trial of Lenalidomide (REVLIMID [®]) with Bortezomib (VELCADE [®]) in Relapsed and Refractory Multiple Myeloma.. Blood, 2005, 106, 365-365.	0.6	17
496	Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.. Blood, 2007, 110, 1164-1164.	0.6	17
497	A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population. Blood, 2010, 116, 1951-1951.	0.6	17
498	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 2016, 128, 976-976.	0.6	17
499	Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. British Journal of Haematology, 2015, 170, 66-79.	1.2	16
500	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <sc>PANORAMA</sc> 1 trial. British Journal of Haematology, 2017, 179, 66-74.	1.2	16
501	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. Cells, 2020, 9, 378.	1.8	16
502	Molecular dynamics of targeting CD38 in multiple myeloma. British Journal of Haematology, 2021, 193, 581-591.	1.2	16
503	Effect of age and frailty on the efficacy and tolerability of once-a-week selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. American Journal of Hematology, 2021, 96, 708-718.	2.0	16
504	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. Hematology American Society of Hematology Education Program, 2014, 2014, 255-261.	0.9	16

#	ARTICLE	IF	CITATIONS
505	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. <i>Blood</i> , 2008, 112, 93-93.	0.6	16
506	Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. <i>Blood</i> , 2011, 118, 476-476.	0.6	16
507	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , 2012, 120, 202-202.	0.6	16
508	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenström Macroglobulinemia. <i>Blood</i> , 2014, 124, 3081-3081.	0.6	16
509	Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. <i>Blood</i> , 2014, 124, 3453-3453.	0.6	16
510	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	16
511	Recent Advances in the Treatment of Multiple Myeloma. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 381-393.	0.9	15
512	Use of defibrotide in the treatment and prevention of veno-occlusive disease. <i>Expert Review of Hematology</i> , 2009, 2, 365-376.	1.0	15
513	Bortezomib and dexamethasone induction for multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 8-10.	12.5	15
514	Novel Targeted Agents in the Treatment of Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 903-925.	0.9	15
515	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	2.0	15
516	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603.	2.0	15
517	Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISM trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 8001-8001.	0.8	15
518	A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). <i>Journal of Clinical Oncology</i> , 2019, 37, 8004-8004.	0.8	15
519	Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. <i>Blood Advances</i> , 2022, 6, 181-188.	2.5	15
520	Proteasome inhibition as a therapeutic strategy for hematologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 465-476.	1.1	14
521	Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 529-539.	2.0	14
522	Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. <i>Blood</i> , 2010, 116, 621-621.	0.6	14

#	ARTICLE	IF	CITATIONS
523	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3483-3483.	0.6	14
524	Characterization of haematological parameters with bortezomib+melphalan+prednisone <i>versus</i> melphalan+prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. <i>British Journal of Haematology</i> , 2011, 153, 212-221.	1.2	13
525	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	3.3	13
526	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019, 134, 3140-3140.	0.6	13
527	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8519-8519.	0.8	13
528	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1078-1087.	3.3	13
529	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 460-473.	0.2	13
530	Plasma Cell Problems. <i>Journal of Clinical Oncology</i> , 2005, 23, 3138-3140.	0.8	12
531	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 551-566.	1.1	12
532	Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. <i>Blood</i> , 2013, 121, 858-858.	0.6	12
533	Multiple Myeloma in Pregnancyâ€”A Review of the Literature and a Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e39-e45.	0.2	12
534	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018, 32, 2032-2036.	3.3	12
535	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN 503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019, 186, e35-e39.	1.2	12
536	OP-106 Horizon â€” Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. <i>Blood</i> , 2018, 132, 600-600.	0.6	12
537	ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). <i>Blood</i> , 2019, 134, 3124-3124.	0.6	12
538	Defibrotide (DF) in the Treatment of Severe Hepatic Venous Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.. <i>Blood</i> , 2009, 114, 654-654.	0.6	12
539	Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2010, 116, 3013-3013.	0.6	12
540	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1969-1969.	0.6	12

#	ARTICLE	IF	CITATIONS
541	A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma. <i>Blood</i> , 2013, 122, 1976-1976.	0.6	12
542	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4764-4764.	0.6	12
543	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015, 126, 3036-3036.	0.6	12
544	Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.. <i>Blood</i> , 2007, 110, 3507-3507.	0.6	12
545	Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple Myeloma. <i>Blood</i> , 2012, 120, 3986-3986.	0.6	12
546	Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. <i>Cancer</i> , 2022, 128, 1996-2004.	2.0	12
547	Emerging drugs in multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 155-163.	1.0	11
548	Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. <i>Expert Review of Hematology</i> , 2017, 10, 933-939.	1.0	11
549	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019, 102, 494-503.	1.1	11
550	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1850-1859.	0.6	11
551	Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study Oâ€œ12â€œM1. <i>British Journal of Haematology</i> , 2021, 193, 1105-1109.	1.2	11
552	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib+â€œdexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 20.	2.8	11
553	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	6.9	11
554	ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. <i>Science Advances</i> , 2021, 7, .	4.7	11
555	High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma. <i>Blood</i> , 2020, 136, 4-5.	0.6	11
556	Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 3691-3691.	0.6	11
557	Lack of Response to Vaccination in MGUS and Stable Myeloma.. <i>Blood</i> , 2009, 114, 1852-1852.	0.6	11
558	Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response. <i>Blood</i> , 2011, 118, 1881-1881.	0.6	11

#	ARTICLE	IF	CITATIONS
559	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , 2012, 120, 450-450.	0.6	11
560	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , 2014, 124, 31-31.	0.6	11
561	An update of novel therapeutic approaches for multiple myeloma. <i>Current Treatment Options in Oncology</i> , 2004, 5, 227-238.	1.3	10
562	Case 38-2004. <i>New England Journal of Medicine</i> , 2004, 351, 2637-2645.	13.9	10
563	Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone. <i>Journal of Clinical Oncology</i> , 2012, 30, e175-e179.	0.8	10
564	The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. <i>European Journal of Haematology</i> , 2012, 88, 446-449.	1.1	10
565	Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. <i>British Journal of Haematology</i> , 2016, 173, 82-88.	1.2	10
566	Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1291-1301.	1.4	10
567	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1975-1985.	0.9	10
568	Maintenance and continuous therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 751-764.	1.1	10
569	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 752-765.	0.2	10
570	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: <scp>ICARIA&MM</scp> subgroup analysis. <i>American Journal of Hematology</i> , 2021, 96, E423-E427.	2.0	10
571	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019, 134, 3125-3125.	0.6	10
572	Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.. <i>Blood</i> , 2007, 110, 1170-1170.	0.6	10
573	Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1179-1179.	0.6	10
574	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). <i>Blood</i> , 2015, 126, 1827-1827.	0.6	10
575	Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells.. <i>Blood</i> , 2007, 110, 1519-1519.	0.6	10
576	Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2008, 112, 2648-2648.	0.6	10

#	ARTICLE	IF	CITATIONS
577	Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. <i>Oncology</i> , 2010, 24, 22-9.	0.4	10
578	Clinical Translation in Multiple Myeloma: From Bench to Bedside. <i>Seminars in Oncology</i> , 2013, 40, 549-553.	0.8	9
579	Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 583-587.	1.2	9
580	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010, 116, 3952-3952.	0.6	9
581	Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011, 118, 301-301.	0.6	9
582	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. <i>Blood</i> , 2011, 118, 634-634.	0.6	9
583	Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study. <i>Blood</i> , 2010, 116, 3023-3023.	0.6	9
584	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. <i>Blood</i> , 2021, 138, 162-162.	0.6	9
585	Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. <i>British Journal of Haematology</i> , 2022, 199, 190-204.	1.2	9
586	Novel biologically based therapies for multiple myeloma. <i>International Journal of Hematology</i> , 2002, 76, 340-341.	0.7	8
587	Management of Relapsed and Relapsed Refractory Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1175-1215.	0.9	8
588	Bortezomib in the management of multiple myeloma. <i>Cancer Management and Research</i> , 2009, Volume 1, 107-117.	0.9	8
589	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide+dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	1.1	8
590	Randomized, placebo-controlled, phase 3 study of perfosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020, 1, 94-102.	0.4	8
591	Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class refractory multiple myeloma. <i>EJHaem</i> , 2021, 2, 48-55.	0.4	8
592	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	1.1	8
593	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	1.1	8
594	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. <i>Bone Marrow Transplantation</i> , 2021, 56, 2889-2896.	1.3	8

#	ARTICLE	IF	CITATIONS
595	Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab. <i>Blood</i> , 2019, 134, 1883-1883.	0.6	8
596	Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1857-1857.	0.6	8
597	Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 1503-1503.	0.6	8
598	PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo.. <i>Blood</i> , 2005, 106, 247-247.	0.6	8
599	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 303-303.	0.6	8
600	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 4217-4217.	0.6	8
601	Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8014-8014.	0.8	8
602	Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 239-246.	1.1	7
603	Emerging Trends in the Clinical Use of Bortezomib in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 84-88.	1.4	7
604	Re: When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival. <i>Journal of the National Cancer Institute</i> , 2008, 100, 373-373.	3.0	7
605	Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma. <i>Lancet Oncology</i> , The, 2010, 11, 1014-1016.	5.1	7
606	The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*. <i>European Journal of Haematology</i> , 2012, 88, 1-7.	1.1	7
607	Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e353-e354.	0.2	7
608	Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e33.	0.2	7
609	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 58-64.e1.	0.9	7
610	Clinical benefit of ixazomib plus lenalidomide–dexamethasone in myeloma patients with non–canonical NF–B pathway activation. <i>European Journal of Haematology</i> , 2020, 105, 274-285.	1.1	7
611	Proteasome inhibitors as therapeutics. <i>Essays in Biochemistry</i> , 2005, 41, 205-218.	2.1	7
612	Defibrotide (DF) Targets Tumor-Microenvironmental Interactions and Sensitizes Multiple Myeloma and Solid Tumor Cells to Cytotoxic Chemotherapeutics.. <i>Blood</i> , 2004, 104, 286-286.	0.6	7

#	ARTICLE	IF	CITATIONS
613	A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).. Blood, 2006, 108, 3582-3582.	0.6	7
614	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. Blood, 2008, 112, 832-832.	0.6	7
615	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. Blood, 2009, 114, 132-132.	0.6	7
616	Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma. Blood, 2014, 124, 4772-4772.	0.6	7
617	Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. Blood, 2015, 126, 4220-4220.	0.6	7
618	Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8014-8014.	0.8	7
619	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. British Journal of Haematology, 2022, 196, 639-648.	1.2	7
620	Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. Blood, 2010, 116, 456-456.	0.6	7
621	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. Blood, 2021, 138, 2852-2852.	0.6	7
622	Defibrotide Therapy for SARS-CoV-2 ARDS. Chest, 2022, 162, 346-355.	0.4	7
623	Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. American Journal of Hematology, 2022, 97, .	2.0	7
624	Toward a new therapeutic backbone in myeloma. Blood, 2007, 109, 2672-2673.	0.6	6
625	The comprehensive clinical management of multiple myeloma and related-plasma cell disorders. Expert Review of Hematology, 2014, 7, 1-3.	1.0	6
626	The challenge of cross-trial comparisons using limited data. Haematologica, 2014, 99, e145-e146.	1.7	6
627	Treatment of Relapsed/Refractory Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 169-194.	0.2	6
628	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S249-S250.	0.2	6
629	Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer Journal, 2020, 10, 29.	2.8	6
630	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opinion on Therapeutic Targets, 2021, 25, 423-433.	1.5	6

#	ARTICLE	IF	CITATIONS
631	Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Review of Hematology, 2021, 14, 697-706.	1.0	6
632	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncology, 2021, 17, 4797-4812.	1.1	6
633	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. Blood, 2018, 132, 749-749.	0.6	6
634	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. Blood, 2019, 134, 3169-3169.	0.6	6
635	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis. Blood, 2020, 136, 15-17.	0.6	6
636	IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.. Blood, 2004, 104, 2403-2403.	0.6	6
637	Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.. Blood, 2006, 108, 3532-3532.	0.6	6
638	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 3700-3700.	0.6	6
639	Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.. Blood, 2009, 114, 2890-2890.	0.6	6
640	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. Blood, 2010, 116, 986-986.	0.6	6
641	PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma. Blood, 2012, 120, 1852-1852.	0.6	6
642	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. Blood, 2016, 128, 3326-3326.	0.6	6
643	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. Blood, 2021, 138, 3793-3793.	0.6	6
644	Does maintenance therapy with thalidomide benefit patients with multiple myeloma?. Nature Clinical Practice Oncology, 2007, 4, 394-395.	4.3	5
645	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€™2. Mayo Clinic Proceedings, 2010, 85, 197-199.	1.4	5
646	Evolving Strategies in the Initial Treatment of Multiple Myeloma. Seminars in Oncology, 2013, 40, 592-601.	0.8	5
647	ICARIA-MM study: efficacy analysis according to prior lines of treatment. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e245-e246.	0.2	5
648	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 797-803.	0.2	5

#	ARTICLE	IF	CITATIONS
649	Targeting Bcl-2 as Therapy for Multiple Myeloma.. Blood, 2005, 106, 109-109.	0.6	5
650	Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.. Blood, 2005, 106, 1571-1571.	0.6	5
651	Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Venous Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).. Blood, 2010, 116, 3481-3481.	0.6	5
652	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. Blood, 2010, 116, 990-990.	0.6	5
653	Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). Blood, 2011, 118, 2933-2933.	0.6	5
654	Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). Blood, 2011, 118, 479-479.	0.6	5
655	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes. Blood, 2012, 120, 4072-4072.	0.6	5
656	Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Blood, 2013, 122, 4402-4402.	0.6	5
657	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study). Blood, 2015, 126, 3055-3055.	0.6	5
658	Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. Journal of Clinical Oncology, 2015, 33, 8526-8526.	0.8	5
659	HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).. Journal of Clinical Oncology, 2020, 38, e20570-e20570.	0.8	5
660	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. Seminars in Oncology, 2022, 49, 19-26.	0.8	5
661	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer Journal, 2022, 12, 63.	2.8	5
662	Hemostatic Complications of Hematopoietic Stem Cell Transplantation: From Hemorrhage to Microangiopathies and VOD. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 50-53.	0.5	4
663	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. British Journal of Haematology, 2006, 132, 698-704.	1.2	4
664	Improving the therapeutic index in myeloma. Blood, 2010, 116, 4733-4734.	0.6	4
665	Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws. Biology of Blood and Marrow Transplantation, 2016, 22, 344-348.	2.0	4
666	Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert Opinion on Orphan Drugs, 2019, 7, 337-347.	0.5	4

#	ARTICLE	IF	CITATIONS
667	Pomalidomide in lenalidomideâ€refractory multiple myeloma: Far from futile. British Journal of Haematology, 2020, 188, 483-485.	1.2	4
668	Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 88.e1-88.e6.	0.6	4
669	Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer Journal, 2021, 11, 55.	2.8	4
670	ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)â€Optimal dose, updated efficacy and safety results.. Journal of Clinical Oncology, 2021, 39, 8037-8037.	0.8	4
671	Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance) Tj ETQq1 1 0.7843 1.4gBT /Overlock 10	0.6	4
672	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application. Blood, 2020, 136, 7-8.	0.6	4
673	Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.. Blood, 2006, 108, 3485-3485.	0.6	4
674	Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. Blood, 2010, 116, 3051-3051.	0.6	4
675	Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT). Blood, 2012, 120, 4053-4053.	0.6	4
676	Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma. Blood, 2013, 122, 1970-1970.	0.6	4
677	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. Blood, 2014, 124, 2120-2120.	0.6	4
678	Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2015, 126, 4256-4256.	0.6	4
679	Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.. Journal of Clinical Oncology, 2014, 32, 8588-8588.	0.8	4
680	Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2018, 36, 8038-8038.	0.8	4
681	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. Blood, 2017, 130, 902-902.	0.6	4
682	Pomalidomideâ€bortezomibâ€dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISM. Cancer Science, 2020, 111, 2116-2122.	1.7	4
683	HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents. Blood, 2020, 136, 2-4.	0.6	4
684	Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clinical Advances in Hematology and Oncology, 2006, 4, 1; discussion 8; suppl 13.	0.3	4

#	ARTICLE	IF	CITATIONS
685	Can thalidomide improve outcome in patients with multiple myeloma?. Nature Clinical Practice Oncology, 2006, 3, 590-591.	4.3	3
686	Advances in the treatment of monoclonal gammopathies: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics: Targets and Therapy, 2008, 2, 419.	3.0	3
687	Reply to C.A. Dasanu et al. Journal of Clinical Oncology, 2009, 27, 2294-2296.	0.8	3
688	Defibrotide for the Treatment of Severe Hepatic Venous Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. Biology of Blood and Marrow Transplantation, 2015, 21, S110.	2.0	3
689	Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e283.	0.2	3
690	Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: Defibrotide as an endothelium-protective, targeted therapy. EJHaem, 2021, 2, 680-681.	0.4	3
691	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis. Blood, 2020, 136, 41-43.	0.6	3
692	Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.. Blood, 2004, 104, 2404-2404.	0.6	3
693	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. Blood, 2004, 104, 2405-2405.	0.6	3
694	Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.. Blood, 2004, 104, 751-751.	0.6	3
695	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. Blood, 2005, 106, 3380-3380.	0.6	3
696	Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma. Blood, 2008, 112, 3662-3662.	0.6	3
697	Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.. Blood, 2009, 114, 1871-1871.	0.6	3
698	Safety of Defibrotide (DF) In Stem Cell Transplant (SCT) Patients (Pts).. Blood, 2010, 116, 3482-3482.	0.6	3
699	Defibrotide (DF) In the Treatment of Severe Hepatic Venous Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol. Blood, 2010, 116, 906-906.	0.6	3
700	Defibrotide (DF) in the Treatment of Hepatic Venous Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol. Blood, 2011, 118, 487-487.	0.6	3
701	Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). Blood, 2012, 120, 4039-4039.	0.6	3
702	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. Blood, 2015, 126, 3031-3031.	0.6	3

#	ARTICLE	IF	CITATIONS
703	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 243-243.	0.6	3
704	Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study. <i>Blood</i> , 2016, 128, 66-66.	0.6	3
705	JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.. <i>Blood</i> , 2004, 104, 3413-3413.	0.6	3
706	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.. <i>Blood</i> , 2008, 112, 1716-1716.	0.6	3
707	Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.. <i>Blood</i> , 2009, 114, 2846-2846.	0.6	3
708	Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing. <i>Blood</i> , 2011, 118, 1838-1838.	0.6	3
709	The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone. <i>Blood</i> , 2019, 134, 3487-3487.	0.6	3
710	Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1613-1613.	0.6	3
711	Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 617-626.	0.5	3
712	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, 562-573.	2.0	3
713	IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. <i>Oncology</i> , 2013, 27, 803-4, 806.	0.4	3
714	Melflufen for the treatment of multiple myeloma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 371-382.	1.3	3
715	Lenalidomide, bortezomib, and dexamethasone (Rvd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4-LBA4.	0.8	3
716	Management Strategies for Relapsed Multiple Myeloma. <i>American Journal of Cancer</i> , 2006, 5, 393-409.	0.4	2
717	Emerging Therapies for Multiple Myeloma. <i>American Journal of Cancer</i> , 2006, 5, 141-153.	0.4	2
718	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. <i>Nature Precedings</i> , 2008, , .	0.1	2
719	THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010009.	0.5	2
720	Setting the standard for newly diagnosed multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 255-256.	12.5	2

#	ARTICLE	IF	CITATIONS
721	Dual inhibition of oncogenic targets for B-cell malignancies. <i>Lancet Oncology</i> , The, 2016, 17, 547-549.	5.1	2
722	The Future of Myeloma Therapy: One Size Does Not Fit All. <i>Journal of Oncology Practice</i> , 2016, 12, 295-296.	2.5	2
723	IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. <i>International Journal of Dermatology</i> , 2017, 56, 1058-1060.	0.5	2
724	Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e352-e353.	0.2	2
725	The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data. <i>Blood</i> , 2018, 132, 1967-1967.	0.6	2
726	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis. <i>Blood</i> , 2020, 136, 22-23.	0.6	2
727	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients. <i>Blood</i> , 2020, 136, 44-46.	0.6	2
728	Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.. <i>Blood</i> , 2006, 108, 3468-3468.	0.6	2
729	Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.. <i>Blood</i> , 2007, 110, 1185-1185.	0.6	2
730	Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. <i>Blood</i> , 2007, 110, 284-284.	0.6	2
731	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	0.6	2
732	A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models.. <i>Blood</i> , 2008, 112, 1719-1719.	0.6	2
733	Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 1943-1943.	0.6	2
734	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. <i>Blood</i> , 2010, 116, 3803-3803.	0.6	2
735	Blockade of XBP1 Splicing by Inhibition of IRE1 \pm Is a Promising Therapeutic Option in Multiple Myeloma. <i>Blood</i> , 2011, 118, 133-133.	0.6	2
736	A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma " Preliminary Safety Data. <i>Blood</i> , 2011, 118, 1873-1873.	0.6	2
737	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide., <i>Blood</i> , 2011, 118, 3966-3966.	0.6	2
738	Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study. <i>Blood</i> , 2012, 120, 4052-4052.	0.6	2

#	ARTICLE	IF	CITATIONS
739	Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1869-1869.	0.6	2
740	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2015, 126, 4246-4246.	0.6	2
741	Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 169.	2.8	2
742	Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.. <i>Blood</i> , 2004, 104, 1498-1498.	0.6	2
743	Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3396-3396.	0.6	2
744	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenstrom's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. <i>Blood</i> , 2010, 116, 2988-2988.	0.6	2
745	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. <i>Blood</i> , 2014, 124, 27-27.	0.6	2
746	Pomalidomide, bortezomib, and dexamethasone (PVD) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISM.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20562-e20562.	0.8	2
747	Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation. <i>Oncology</i> , 2003, 17, 1063-5.	0.4	2
748	New therapies for the treatment of multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2005, 3, 345-6.	0.3	2
749	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210884.	1.1	2
750	Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2403-2412.	0.6	2
751	A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8012-8012.	0.8	2
752	Allogeneic Transplantation in Multiple Myeloma: A Potential Renaissance in the Era of Novel Therapies?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1078-1079.	2.0	1
753	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1089-1108.	0.5	1
754	Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1491-1501.	0.5	1
755	Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S337.	0.2	1
756	Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S335-S336.	0.2	1

#	ARTICLE	IF	CITATIONS
757	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. Hematologic Malignancies, 2018, , 73-96.	0.2	1
758	Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation â€“ a case series. British Journal of Haematology, 2021, 193, e36-e38.	1.2	1
759	Multiple myeloma triplet therapies: baseline characteristics and control groups â€“ Authors' reply. Lancet, The, 2021, 397, 1621-1623.	6.3	1
760	Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.. Journal of Clinical Oncology, 2021, 39, 8048-8048.	0.8	1
761	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409.		1
762	Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation. Pediatric Oncology, 2014, , 77-102.	0.5	1
763	Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management. , 2011, , 95-105.		1
764	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. Blood, 2018, 132, 1960-1960.	0.6	1
765	Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1. Blood, 2019, 134, 1839-1839.	0.6	1
766	A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action. Blood, 2020, 136, 34-34.	0.6	1
767	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. Blood, 2004, 104, 2456-2456.	0.6	1
768	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. Blood, 2005, 106, 3398-3398.	0.6	1
769	Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone.. Blood, 2005, 106, 4447-4447.	0.6	1
770	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. Blood, 2006, 108, 3460-3460.	0.6	1
771	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenströ̀m Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4493-4493.	0.6	1
772	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. Blood, 2008, 112, 1011-1011.	0.6	1
773	A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism. Blood, 2010, 116, 3007-3007.	0.6	1
774	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 1874-1874.	0.6	1

#	ARTICLE	IF	CITATIONS
775	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 2705-2705.	0.6	1
776	Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2011, 118, 2706-2706.	0.6	1
777	Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study. <i>Blood</i> , 2011, 118, 3968-3968.	0.6	1
778	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. <i>Blood</i> , 2012, 120, 4070-4070.	0.6	1
779	Defibrotide for the Treatment of Hepatic Venno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients. <i>Blood</i> , 2014, 124, 1138-1138.	0.6	1
780	Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method. <i>Blood</i> , 2014, 124, 2036-2036.	0.6	1
781	A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism. <i>Blood</i> , 2015, 126, 3000-3000.	0.6	1
782	Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival. <i>Blood</i> , 2015, 126, 3029-3029.	0.6	1
783	Defibrotide for the Treatment of Hepatic Venno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. <i>Blood</i> , 2015, 126, 737-737.	0.6	1
784	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2122-2122.	0.6	1
785	CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myeloma. Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO). <i>Journal of Clinical Oncology</i> , 2017, 35, 8037-8037.	0.8	1
786	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2012, 19, 734-744.	0.9	1
787	TGF- β 2 Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. <i>Blood</i> , 2004, 104, 2355-2355.	0.6	1
788	The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication. <i>Blood</i> , 2006, 108, 3452-3452.	0.6	1
789	Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma. <i>Blood</i> , 2007, 110, 2524-2524.	0.6	1
790	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. <i>Blood</i> , 2007, 110, 4494-4494.	0.6	1
791	In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway. <i>Blood</i> , 2007, 110, 540-540.	0.6	1
792	Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease. <i>Blood</i> , 2007, 110, 1509-1509.	0.6	1

#	ARTICLE	IF	CITATIONS
793	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. <i>Blood</i> , 2010, 116, 1963-1963.	0.6	1
794	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 3263-3263.	0.6	1
795	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. <i>Blood</i> , 2018, 132, 1981-1981.	0.6	1
796	Melflufen – A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Oncology & Hematology Review</i> , 2020, 16, 12.	0.2	1
797	COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 3801-3801.	0.6	1
798	Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial. <i>Blood</i> , 2021, 138, 2733-2733.	0.6	1
799	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020, 136, 6-8.	0.6	1
800	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis. <i>Blood</i> , 2020, 136, 27-29.	0.6	1
801	Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma. <i>Blood</i> , 2020, 136, 25-26.	0.6	1
802	MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. <i>Oncology</i> , 2011, 25, 594, 596.	0.4	1
803	TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA. , 0, , 46-63.		0
804	Proteasome Inhibition. <i>American Journal of Cancer</i> , 2004, 3, 271-279.	0.4	0
805	Proteasome inhibition as an anticancer target. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 698-698.	21.5	0
806	The emerging role of novel therapeutic agents in the management of patients with multiple myeloma. <i>Community Oncology</i> , 2006, 3, 575-582.	0.2	0
807	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Targeted Oncology</i> , 2008, 3, 19-29.	1.7	0
808	Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S40-S42.	1.4	0
809	A new standard of care in newly diagnosed multiple myeloma. <i>Lancet, The</i> , 2010, 376, 2043-2044.	6.3	0
810	Treatment of relapsed/refractory myeloma. , 0, , 144-166.		0

#	ARTICLE	IF	CITATIONS
811	The impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction. Journal of Hematological Malignancies, 2013, 3, .	0.0	0
812	Safety of Live-attenuated Zoster Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide after Autologous Stem Cell Transplantation.. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
813	Safety of MMR Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation.. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
814	Towards a better understanding of monoclonal gammopathy of renal significance. British Journal of Haematology, 2019, 186, 653-654.	1.2	0
815	The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. British Journal of Haematology, 2021, 193, 213-215.	1.2	0
816	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. Journal of Clinical Oncology, 2021, 39, 12082-12082.	0.8	0
817	Reply to G. R. Mohyuddin et al and A. Garfall et al. Journal of Clinical Oncology, 2021, , JCO2102081.	0.8	0
818	Hepatic Venous Occlusive Disease. , 2004, , 297-314.		0
819	Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. Blood, 2004, 104, 2401-2401.	0.6	0
820	Bortezomib Targets Multiple Myeloma Endothelial Cells.. Blood, 2004, 104, 4903-4903.	0.6	0
821	Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500K Single Nucleotide Polymorphism Array Analysis.. Blood, 2005, 106, 1551-1551.	0.6	0
822	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. Blood, 2005, 106, 5150-5150.	0.6	0
823	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. Blood, 2005, 106, 627-627.	0.6	0
824	Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma.. Blood, 2006, 108, 3080-3080.	0.6	0
825	Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw.. Blood, 2006, 108, 3591-3591.	0.6	0
826	Novel Therapeutic Options for the Treatment of Relapsed and Relapsed, Refractory Myeloma. Translational Medicine Series, 2007, , 169-196.	0.0	0
827	The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma. , 2008, , 291-308.		0
828	The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma. , 2008, , 239-252.		0

#	ARTICLE	IF	CITATIONS
829	Hepatic Veno-Occlusive Disease. , 2008, , 467-493.		0
830	Immunomodulatory Effects of Lenalidomide and Bortezomib on Bone Marrow Stroma Cell and CD4 T Cell Interaction in Multiple Myeloma.. Blood, 2008, 112, 1690-1690.	0.6	0
831	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. Blood, 2008, 112, 2737-2737.	0.6	0
832	Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. Blood, 2009, 114, 1722-1722.	0.6	0
833	Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.. Blood, 2009, 114, 950-950.	0.6	0
834	A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.. Blood, 2009, 114, 3830-3830.	0.6	0
835	PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo.. Blood, 2009, 114, 612-612.	0.6	0
836	Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics. , 2011, , 29-42.		0
837	Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone. Blood, 2010, 116, 618-618.	0.6	0
838	An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway. Blood, 2010, 116, 2992-2992.	0.6	0
839	Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. Blood, 2010, 116, 1838-1838.	0.6	0
840	Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function. Blood, 2010, 116, 451-451.	0.6	0
841	Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation. Blood, 2010, 116, 4064-4064.	0.6	0
842	Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications. Blood, 2010, 116, 5016-5016.	0.6	0
843	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	0.6	0
844	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. Blood, 2011, 118, 815-815.	0.6	0
845	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2011, 118, 4134-4134.	0.6	0
846	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. Blood, 2011, 118, 1442-1442.	0.6	0

#	ARTICLE	IF	CITATIONS
847	Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes. Blood, 2011, 118, 1377-1377.	0.6	0
848	A Novel Acanthoic Acid Analog NPI-1342 Blocks I κ B Kinase- $\hat{\pm}$ and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells. Blood, 2011, 118, 1841-1841.	0.6	0
849	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. Blood, 2011, 118, 3989-3989.	0.6	0
850	Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. Blood, 2012, 120, 565-565.	0.6	0
851	Novel Agents in Multiple Myeloma. , 2013, , 215-228.		0
852	Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells. Blood, 2012, 120, 1847-1847.	0.6	0
853	Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. Blood, 2012, 120, 1812-1812.	0.6	0
854	Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents. Blood, 2012, 120, 3995-3995.	0.6	0
855	Antitumor Activities Of An Oral Selective HSP90 $\hat{\pm}$ / $\hat{\pm}$ Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma. Blood, 2013, 122, 4429-4429.	0.6	0
856	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). Blood, 2013, 122, 1854-1854.	0.6	0
857	Mimicking Myeloma Niche Ex Vivo. Blood, 2014, 124, 2076-2076.	0.6	0
858	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. Blood, 2014, 124, 3404-3404.	0.6	0
859	Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Venous Occlusive Disease. Blood, 2014, 124, 2470-2470.	0.6	0
860	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	0.6	0
861	Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide. Blood, 2015, 126, 4253-4253.	0.6	0
862	Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study. Blood, 2015, 126, 5322-5322.	0.6	0
863	Targeting Replicative Stress to Treat Hematological Disorders. Blood, 2015, 126, 2419-2419.	0.6	0
864	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	0.6	0

#	ARTICLE	IF	CITATIONS
865	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 2134-2134.	0.6	0
866	Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigen-Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers. <i>Blood</i> , 2016, 128, 5689-5689.	0.6	0
867	A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5815-5815.	0.6	0
868	Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen. <i>Blood</i> , 2018, 132, 3234-3234.	0.6	0
869	Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation " Results from the Tourmaline-MM1 Study. <i>Blood</i> , 2018, 132, 473-473.	0.6	0
870	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradable Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. <i>Blood</i> , 2018, 132, 1367-1367.	0.6	0
871	Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8043-8043.	0.8	0
872	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degradable Oncoproteins. <i>Blood</i> , 2019, 134, 318-318.	0.6	0
873	Revised international staging system allocation in the ICARIA-MM study: Practical challenges and impact on outcome. <i>EJHaem</i> , 0, , .	0.4	0
874	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses. <i>Blood</i> , 2021, 138, 2732-2732.	0.6	0
875	OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis. <i>Blood</i> , 2021, 138, 4780-4780.	0.6	0
876	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status. <i>Blood</i> , 2021, 138, 4779-4779.	0.6	0
877	Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma. <i>Blood</i> , 2021, 138, 4969-4969.	0.6	0
878	Sinusoidal Obstruction Syndrome/Hepatic Venous Occlusive Disease. , 2022, , 143-163.		0
879	TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 31-31.	0.6	0
880	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations. <i>Blood</i> , 2020, 136, 20-22.	0.6	0
881	Variation in the Treatment of Multiple Myeloma in the Real World. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
882	DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
883	Current antibody-based therapies for the treatment of multiple myeloma. Clinical Advances in Hematology and Oncology, 2020, 18, 736-748.	0.3	0